Cardiac amyloidosis: Description of a series of 143 cases

Barge-Caballero, 2017, How to face a clinical suspicion of cardiac amyloidosis? A practical approach to the diagnosis, Cardiocore, 52, 27, 10.1016/j.carcor.2016.05.002 García-Pavía, 2021, Transthyretin amyloid cardiomyopathy, Med Clin (Barc), 156, 126 Donnelly, 2017, Cardiac amyloidosis: an update on diagnosis and treatment, Cleve Clin J Med, 84, 12, 10.3949/ccjm.84.s3.02 Gillmore, 2016, Non-biopsy diagnosis of cardiac transthyretin amyloidosis, Circulation, 133, 2404, 10.1161/CIRCULATIONAHA.116.021612 Maurer, 2018, Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy, N Engl J Med, 379, 1007, 10.1056/NEJMoa1805689 Palladini, 2020, Management of AL amyloidosis in 2020, Hematology Am Soc Hematol Educ Program, 2020, 363, 10.1182/hematology.2020006913 López-Sainz, 2021, Clinical profile and outcome of cardiac amyloidosis in a Spanish referral center, Rev Esp Cardiol (Engl Ed), 74, 149, 10.1016/j.recesp.2019.12.017 Barge-Caballero, 2021, Light chain and transthyretin cardiac amyloidosis: clinical characteristics, natural history and prognostic factors, Med Clin (Barc), 156, 369, 10.1016/j.medcli.2020.04.031 Comenzo, 2012, Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis, Leukemia, 26, 2317, 10.1038/leu.2012.100 Kyle, 1992, Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989, Blood, 79, 1817, 10.1182/blood.V79.7.1817.1817 Quock, 2018, Epidemiology of AL amyloidosis: a real-world study using US claims data, Blood Adv, 2, 1046, 10.1182/bloodadvances.2018016402 Pinney, 2013, Systemic amyloidosis in England: an epidemiological study, Br J Haematol, 161, 525, 10.1111/bjh.12286 García-Pavía, 2021, Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases, Eur J Heart Fail, 23, 512, 10.1002/ejhf.2140 Lane, 2019, Natural history, quality of life and outcome in cardiac transthyretin amyloidosis, Circulation, 140, 16, 10.1161/CIRCULATIONAHA.118.038169 Maurer, 2016, Genotype and phenotype of transthyretin cardiac amyloidosis in the United States: the Transthyretin Amyloid Outcome Survey (THAOS), J Am Coll Cardiol, 68, 161, 10.1016/j.jacc.2016.03.596 Czobor, 2019, Amyloid cardiomyopathy in a large integrated health care system, Am Heart J, 216, 42, 10.1016/j.ahj.2019.06.008 Donnelly, 2019, Carpal tunnel syndrome: a potential early, red-flag sign of amyloidosis, J Hand Surg Am, 44, 868, 10.1016/j.jhsa.2019.06.016 Barge-Caballero, 2019, Quadriceps tendon rupture in wild-type transthyretin amyloidosis (ATTRwt), Eur Heart J, 40, 1307, 10.1093/eurheartj/ehz128 Cyrille, 2014, Prevalence and prognostic significance of low QRS voltage among the three main types of cardiac amyloidosis, Am J Cardiol, 114, 1089, 10.1016/j.amjcard.2014.07.026 Rapezzi, 2009, Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types, Circulation, 120, 1203, 10.1161/CIRCULATIONAHA.108.843334